Amplyx Cleared To Complete Phase II Study Of New Antifungal Class
Fosmanogepix, with safety and efficacy clearances to continue Phase II, could provide an IV-to-oral option for patients with potentially lethal Candida fungal infections.
You may also be interested in...
Pfizer will develop the novel antifungal fosmanogepix. The big pharma has made several other recent anti-infective deals, including when it expanded its BioNTech vaccine alliance to include COVID-19.
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.